

Financial Results Q1 FY22



Safe Harbor Statement

This presentation contains forward-looking statements and information that involve risks, uncertainties and assumptions. Forward-looking statements are all statements that concern plans, objectives, goals, strategies, future events or performance and underlying assumptions and other statements that are other than statements of historical fact, including, but not limited to, those that are identified by the use of words such as "anticipates", "believes", "estimates", "expects", "intends", "plans", "predicts", "projects" and similar expressions. Risks and uncertainties that could affect us include, without limitation:

- General economic and business conditions in India and other key global markets in which we operate;
- The ability to successfully implement our strategy, our research and development efforts, growth & expansion plans and technological changes;
- Changes in the value of the Rupee and other currency changes;
- Changes in the Indian and international interest rates;
- Allocations of funds by the Governments in our key global markets;
- Changes in laws and regulations that apply to our customers, suppliers, and the pharmaceutical industry;
- Increasing competition in and the conditions of our customers, suppliers and the pharmaceutical industry; and
- Changes in political conditions in India and in our key global markets.

Should one or more of such risks and uncertainties materialize, or should any underlying assumption prove incorrect, actual outcomes may vary materially from those indicated in the applicable forward-looking statements.

For more detailed information on the risks and uncertainties associated with the Company's business activities, please see the company's annual report filed in Form 20-F with the US SEC for the fiscal year ended March 31, 2021 and quarterly financial statements filed in Form 6-K with the US SEC for the quarters ended Jun 30, 2020, Sep 30, 2020, Dec 31, 2020 and our other filings with US SEC. Any forward-looking statement or information contained in this presentation speaks only as of the date of the statement. We are not required to update any such statement or information to either reflect events or circumstances that occur after the date the statement or information is made or to account for unanticipated events.



Financial Highlights

Double digit growth in revenues | On track with strategy



* Q4 FY21 financials have been adjusted with an additional charge of Rs. 191 Cr (\$ 26.25 mn) arising out of the arbitration award in favor of Hatchtech towards the Xeglyze product as an adjusting subsequent event for filing IFRS financials with US SEC in Form 20F on June 30, 2021.



Rs. Cr

Dr.Reddy's

P&L Metrics – We continue to invest in brands, digitalization & pipeline for future growth

 $\bullet \bullet \bullet$

Gross margin[^] SG&A Expenses **R&D** Expenses YoY Inc QoQ Inc YoY Inc QoQ Inc 18% 14% 5% 11% 56.0% 53.7% 52.2% 1,505 1,437 1,279 453 409 398 % to Sales % to 28.9% 30.6% 9.0% 8.7% 9.2% 30.4% Sales Q1 Q4 Q4 Q4 Q1 Q1 Q1 Q1 Q1 FY21 FY22 FY21 **FY22 FY22** FY21 FY21 FY21 **FY21**

^ Q1 FY21 margins benefitted from higher export incentives and favorable product mix | Q1 FY22 decline on account of price erosion primarily in US & Europe






Rs. Cr

North America – Benefits from new product launches offset with price erosion

Revenues




- **Revenue:** Growth mainly driven by
 - \circ Contribution from new product launches
 - Market share gain for a few key products
 - Offset with price erosion
- New launches: Six
 - US Icosapent Ethyl Caps, Ertapenam Injection, Sapropterin sachets and Albendazole
 - o Canada Sodium Nitroprusside and Alitretinoin
- US filing update:
 - \circ ANDAs filed 2
 - Cumulative pending for approval 93 (90 ANDAs + 3 NDAs)
 - 47 Para IV filings
 - 24 expected to have FTF status



India – growth driven by new products, covid portfolio & base business traction

Revenues



Revenue: Growth driven by traction in base business, covid product portfolio & new product launches

Six new launches including -

- Sputnik-V vaccine and 2DG for covid.
- Curhealth[™], a nutritional health mix for building immunity.

IQVIA growth rates


June 2021	FTM	MQT	MAT
IPM	12.4%	39.2 [%]	14.5%
Dr. Reddy's	31.7%	60.5 %	19.4 %

We were ranked 9th on FTM basis, 12th on MQT & 11th on MAT basis

FTM: For the month | MQT: Moving quarterly total | MAT: Moving annual total

Emerging Markets – Continued strong growth momentum

Revenues



			₹ Cr
Region	Q1 FY22	YoY Gr	QoQ Gr
Russia	353	8%	-13%
CISR	144	4%	-24%
RoW	416	25%	43%
EM	913	14%	3%

<u>Russia:</u>

- YoY growth driven by base business traction, price increases & new products
- QoQ decline primarily due to tender sales in Q4 FY21

CISR:

• Growth impacted mainly due to lower sales in Ukraine


<u>RoW:</u>

• Growth mainly driven by Brazil, China and Thailand markets



Europe – Growth driven by France, Italy & Spain

Revenues




			₹ Cr
Region	Q1 FY22	YoY Gr	QoQ Gr
Germany	223	1%	0%
UK/OL	92	11%	-3%
France, Italy, Spain & others	84	<i>63</i> %	9%
Europe	399	12 %	1%

- Growth mainly driven by -
 - New product launches
 - Favourable forex movement
 - Volume traction
 - Offset partly by price erosion in the base business
- New market expansion Netherlands, Portugal, Slovakia & Czech Republic



PSAI — Growth impacted due to higher base on account of covid related up-stocking

Revenues





Revenue:


- Decline was on account of -
 - lower base business traction
 - price erosion
 - partly offset by new products
- YoY was also impacted as there was customer stocking-up in Q1 FY21

Filings:

	Q1 FY22
Global DMFs filed incl. in US	30
US DMFs	2



R&D, Capex & Cash flows



Dr.Reddy's

Key Priorities



With focus on execution, we remain confident that our strategy will deliver sustainable growth

Dr.Reddy's

Covid portfolio Update



Covid-19 treatment drugs – We continue to be at the forefront of COVID response

Remdesivir – Moderate to Severe

- <u>Partner</u> : Gilead
- Currently sold in India
- Scaled up production and capacity
- Extension
 - 1 ml liquid (IV/SC) Injection

Molnupiravir – Mild to Moderate

- Partner : MSD
- <u>Status</u> :
- Clinical trial in progress with collaboration of voluntary license holders.
- Interim Data shared with the DCGI

Favipiravir – Mild to Moderate

- <u>Partner</u> : Fujifilm
- Launched in India & a few other countries
- Manufacturing by Fuji film and also by Dr Reddy's

Liposomal Amphotericin B -Mucormycosis

- Re-purposed drug for Mucormycosis
- India approval received in Jun'21
- Launch planning on-going

2-DG – Moderate to Severe

- <u>Partner</u> : DRDO (INMAS)
- Launched in India
- Extension –

٠

- Label expansion for mild patients
- Ph. 3 for expanded indication planned

Other Drugs

Additionally, we are working on repurposing other covid treatment drugs for patients with mild, moderate, severe and critical conditions



Sputnik update

- Manufacturing, clinical and life cycle management update
- Go-to-Market and commercialization update

Supply, Manufacturing and Clinical update

 $\bullet \bullet \bullet$

Supply availability / Domestic manufacturing

- Working with RDIF for ramping-up supplies
- Working closely with six CMOs in India for manufacturing readiness

Sputnik Light

- Russia phase 3 trials will be leveraged for India filing as per recommendation from SEC. Submission will be made soon.
- Trial study on-going in Russia for adolescent segment of the population (12-18 years of age)



Go-to-market and commercialization update

Commercialization

- Commercial scale-up in progress
- We have launched it across 80 cities and 2.5+ Lakh people have been vaccinated so far
- Customer cold chain infrastructure being set-up across 300+ locations

Go-to-market update


- Ensure wide, equitable coverage geography, demographic group, community category
- Prioritize reliable-to-implement routes to customer
- Clear and transparent about our offering and vaccine attributes
- Targeted and measured to ensure the highest standards of safety and efficacy

Sputnik V is proven to be safe and effective across all adult age groups, even in people above 60 years of age & in people with diabetes and hypertension



Svaas





Suboptimal Care & Patient Experience

Delightfully Simple & High-Quality Healthcare

